CPT1A and Hashimoto thyroiditis: The mTOR/ACC1/CPT1A fatty acid oxidation pathway of CD4+T cells in Hashimoto’s thyroiditis was increased, and treatment with Etomoxir could inhibit the activation of this pathway, and reverse the reprogramming of abnormal metabolism in CD4+T cells, thereby reducing Hashimoto’s thyroiditis.